Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months

TARRYTOWN, N.Y. and PARIS , Aug. 30, 2021 /PRNewswire/ — Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks More than seven times as many patients treated with Dupixent plus topical corticosteroids (TCS) achieved clear or almost clear

close

Get every new post delivered right to your inbox.

Original Source